Identifying new ways to predict tuberculosis treatment outcomes
Official title: C3PO - The Candidate Clinical Correlate of Prognostic Outcome for TB Study
Funded at University of California, San Francisco · NIH-11090185 · Data updated 2026-11-12
This study is looking for better ways to check if tuberculosis treatments have worked by examining certain markers in patients after they finish their treatment, so we can help teenagers and adults avoid relapsing in the future.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | July 1, 2024 |
| Project end | May 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $2,655,299 |
| NIH project number | 3U01AI152087-05S1 |
| Project ID | NIH-11090185 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adolescents and adults who have recently completed treatment for drug-susceptible pulmonary tuberculosis.
✕Less likely to help
Patients with drug-resistant forms of tuberculosis or those who have not undergone the standard 4-drug regimen may not benefit from this research.
What this research studies
This research investigates innovative methods to assess the effectiveness of tuberculosis (TB) treatments by analyzing biomarkers in patients at the end of their treatment. Current methods, like sputum cultures, are slow and often unreliable in predicting relapse. By focusing on new non-culture assays, the study aims to find more accurate predictors of microbiologic relapse in adolescents and adults who have completed standard TB treatment. The research is part of a larger network aimed at improving diagnostic tools for TB.
Why it matters
Potential benefit: If successful, this research could lead to faster and more effective treatments for tuberculosis, reducing the risk of relapse.
How similar studies have gone: Previous research has shown promise in using novel biomarkers to predict treatment outcomes in tuberculosis, suggesting that this approach could be effective.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Nahid, Payam — University of California, San Francisco
- Study coordinator: Nahid, Payam
Related research
Other NIH-funded projects on the same topics.
-
How cancer cells use exosomes to evade the immune system
This study is looking at how cancer cells use tiny bubbles called exosomes to hide proteins that can keep your immune system from fighting the tumor, and by figuring this out, the researchers hope to help doctors understand why some people respond well to cancer treatments while others don’t, ultimately aiming to creat
-
Reducing harm from smoking using electronic cigarettes
This study is looking at whether using electronic cigarettes can be a safer option for people who smoke traditional cigarettes, by comparing the health effects and exposure to harmful substances between the two.
-
Understanding how knee pain and knee obesity and muscle loss affect knee osteoarthritis
This project looks at how knee swelling, excess knee fat, and muscle loss relate to pain and structural changes in knee osteoarthritis in adults.
-
Cutaneous opioid signals in skin inflammation
A mentor-identified clinician-researcher at UCSF is studying how natural skin opioids regulate itch and pain in inflammatory skin conditions like eczema and hidradenitis, with plans to map where these opioids come from and how they affect skin nerves.
-
Pooling international data to understand long-term bisphosphonate use and atypical femur fractures
This project combines large patient datasets from multiple countries to understand how long-term bisphosphonate use relates to rare hip and thigh bone fractures, helping doctors and patients make safer treatment choices.
-
Airway cell and immune cell talks in lung transplant failure
This grant tests how airway cells and immune cells interact to drive chronic rejection after lung transplant, with the goal of slowing or preventing scar-like damage.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.